Investor Relations Home

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as oncology.

Stock Quote RIGL (Common Stock) Exchange NASDAQ (US Dollar) Price $5.38 Change (%)   0.23 (4.10%) Volume 702,525 Data as of 11/20/08 4:00 p.m. ET Minimum 20 minute delay Refresh quote

What's New Title   Financial Tearsheet   2007 Annual Report   2008 Proxy Statement   2008 Q3 10-Q

Date Title   11/11/08 Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism First of Phase 2b studies completes patient screening for enrollment SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the previously reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium), the company's oral Syk inhibitor, have been published in the November 2008 issue of Arthritis and Rheumatism. The article, entitled, "Treatment of rheumatoid arthritis with a syk kinase inhibito...  11/11/08 Rigel to Present at the 2008 Credit Suisse Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, Rigel's president and chief executive officer, will present a company overview at the 2008 Credit Suisse Healthcare Conference on Thursday, November 13 at 4:30 p.m. MST. The conference will be held at the Arizona Biltmore Resort in Phoenix, Arizona. To access the live audio webcast or the subsequent archived recording, log on to http://www...

Print Page |  E-mail Page |  RSS Feeds |  E-mail Alerts |  IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.